IRLAB Therapeutics AB (publ)
SSE:IRLAB-A.ST
Overview | Financials
Company Name | IRLAB Therapeutics AB (publ) |
Symbol | IRLAB-A.ST |
Currency | SEK |
Price | 14.45 |
Market Cap | 748,345,270 |
Dividend Yield | 0% |
52-week-range | 5.58 - 18 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Gunnar Olsson |
Website | https://www.irlab.se |
An error occurred while fetching data.
About IRLAB Therapeutics AB (publ)
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD